Takhzyro
Product Images NDC 47783-644

36 FDA label images from Takeda Pharmaceuticals America, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 36 technical images submitted to the FDA as part of the official labeling for Takhzyro (NDC 47783-644). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Logo 1 (Lanadelumab 63)

FDA Label Image

Figure A (Lanadelumab 01)

Figure A (Lanadelumab 01)
An instructional diagram showing the components of a TAKHZYRO syringe: plunger rod, stopper, finger grip with instruction to keep finger grip on at all times, syringe barrel containing medicine, and needle cap. A magnified inset shows the needle inside the cap.*
FDA Label Image

Figure B (Lanadelumab 02)

Figure B (Lanadelumab 02)
An instructional diagram showing four medical supplies: an alcohol swab, a cotton ball or gauze pad, an adhesive bandage, and a sharps container. These items are commonly used for injection site preparation and care.*
FDA Label Image

Image (Lanadelumab 03)

Image (Lanadelumab 03)
An instructional graphic showing a clock-like circle with the words 'Wait 15 minutes' inside. The outer ring is turquoise with a red segment indicating the 15-minute wait duration.*
FDA Label Image

Figure C (Lanadelumab 04)

Figure C (Lanadelumab 04)
An instructional illustration showing a hand removing a green cap from a pre-filled syringe inside an open white box. The packaging appears to contain multiple syringes for subcutaneous injection, consistent with medication administration steps for TAKHZYRO by Takeda Pharmaceuticals America, Inc.*
FDA Label Image

Figure D (Lanadelumab 05)

Figure D (Lanadelumab 05)
An instructional illustration showing two hands being washed under running water from a tap. Blue bubbles or soap lather are visible on the hands, indicating the washing process.*
FDA Label Image

Figure E (Lanadelumab 06)

Figure E (Lanadelumab 06)
An instructional diagram illustrating a prefilled syringe with a magnified view highlighting the area on the syringe where the expiration date is printed. The syringe is designed for TAKHZYRO, an injectable medication labeled by Takeda Pharmaceuticals America, Inc.*
FDA Label Image

Figure F (Lanadelumab 07)

Figure F (Lanadelumab 07)
An instructional illustration showing a hand holding a TAKHZYRO prefilled syringe. The illustration highlights the correct way to visually inspect the syringe through an eye icon, indicating to check the solution and syringe before use.*
FDA Label Image

Figure G (Lanadelumab 08)

Figure G (Lanadelumab 08)
Instructional illustration showing recommended injection sites for TAKHZYRO. It highlights suitable areas for self-injection including the stomach (abdomen) and thighs, and injection sites for caregiver administration including the upper arms, stomach (abdomen), and thighs.*
FDA Label Image

Figure H (Lanadelumab 09)

Figure H (Lanadelumab 09)
An illustration showing a hand holding a cloth or gauze pad, pressing it against a puncture site on the skin of an arm, suggesting post-injection care.*
FDA Label Image

Figure I (Lanadelumab 10)

Figure I (Lanadelumab 10)
An instructional illustration showing two hands demonstrating how to remove a protective cap from a syringe. The left hand is pulling off a small cap, while the right hand holds a syringe with an attached plunger, with arrows indicating the direction to remove the cap.*
FDA Label Image

Figure J (Lanadelumab 11)

Figure J (Lanadelumab 11)
An illustration depicting a hand holding a syringe, positioned to administer an injection. The image is instructional in style, showing proper hand placement on the syringe for injection administration.*
FDA Label Image

Figure K (Lanadelumab 12)

Figure K (Lanadelumab 12)
An instructional illustration showing a person holding their abdomen with one hand. Two blue arrows highlight the hand and the abdominal area, likely indicating the site for injection or medication administration related to TAKHZYRO.*
FDA Label Image

Figure L (Lanadelumab 13)

Figure L (Lanadelumab 13)
Illustration showing an injection technique for TAKHZYRO, with instructions to hold the syringe at a 90-degree angle to the skin for injection, and an alternative angle of 45 degrees indicated in an inset. The image depicts a person pinching the skin on their abdomen to prepare for the injection.*
FDA Label Image

Figure M (Lanadelumab 15)

Figure M (Lanadelumab 15)
An instructional illustration showing the bottom of a syringe barrel and the position of the stopper. The syringe is depicted vertically with a label pointing to the bottom of the barrel and another pointing to the stopper inside the syringe.*
FDA Label Image

Figure N (Lanadelumab 14)

Figure N (Lanadelumab 14)
Instructional diagram showing the technique for injecting TAKHZYRO subcutaneously into the abdomen area. It depicts a hand holding a syringe with an arrow indicating the needle insertion point into the abdominal skin.*
FDA Label Image

Figure O (Lanadelumab 16)

Figure O (Lanadelumab 16)
An instructional illustration showing a hand holding a syringe above a red sharps disposal container with a white lid, demonstrating safe injection needle disposal by inserting the needle into the container.*
FDA Label Image

Figure A (Lanadelumab 17)

Figure A (Lanadelumab 17)
An instructional illustration showing a vial with a plastic cap and a rubber stopper labeled for TAKHZYRO. The diagram details the components of the vial closure system, specifically the plastic cap above the rubber stopper on the vial.*
FDA Label Image

Figure B (Lanadelumab 18)

FDA Label Image

Image (Lanadelumab 19)

FDA Label Image

Figure C (Lanadelumab 20)

Figure C (Lanadelumab 20)
An illustration diagram of a syringe, labeled with its parts including the plunger and barrel. The image is a simple black and white line drawing showing the basic components of a syringe typically used for injecting medication.*
FDA Label Image

Figure D (Lanadelumab 21)

Figure D (Lanadelumab 21)
An instructional diagram showing a needle assembly labeled with parts: 'Needle hub,' 'Cap,' and 'Needle (inside cap). This illustration depicts the components of a needle used for injection.*
FDA Label Image

Figure E (Lanadelumab 22)

Figure E (Lanadelumab 22)
An illustration showing a needle cap labeled with parts: the cap body, needle hub, and the needle inside the cap. The diagram visually identifies these components of a pre-attached needle cap assembly.*
FDA Label Image

Figure F (Lanadelumab 23)

Figure F (Lanadelumab 23)
An illustration of a rectangular sharps disposal container with a lid designed to safely contain used needles or other medical sharps. The container is predominantly gray with dark shading on the lid area.*
FDA Label Image

Figure G (Lanadelumab 24)

Figure G (Lanadelumab 24)
An instructional illustration showing a hand holding a small vial, demonstrating a tilting motion with the vial. This likely depicts how to prepare or mix the contents before use, associated with TAKHZYRO 150 mg/mL or 300 mg/2 mL injection by Takeda Pharmaceuticals America, Inc.*
FDA Label Image

Figure H (Lanadelumab 25)

Figure H (Lanadelumab 25)
An instructional illustration showing a hand holding a vial with the cap being lifted upwards, indicating the removal of the vial cap.*
FDA Label Image

Figure I (Lanadelumab 26)

Figure I (Lanadelumab 26)
An instructional illustration showing a hand peeling off a protective seal from the top of a medication vial, indicating preparation for use. The vial appears to be a clear glass container with a rubber stopper, partially filled with liquid.*
FDA Label Image

Figure J (Lanadelumab 27)

Figure J (Lanadelumab 27)
An instructional diagram showing hands removing the cap from a prefilled syringe, likely demonstrating preparation steps for TAKHZYRO injection.*
FDA Label Image

Figure K (Lanadelumab 28)

Figure K (Lanadelumab 28)
An instructional illustration showing a hand holding a prefilled syringe applying a cap or needle cover, likely related to preparation for injection. No product text or packaging is visible in the image.*
FDA Label Image

Figure L (Lanadelumab 29)

Figure L (Lanadelumab 29)
An instructional illustration showing a close-up of two hands preparing a syringe and vial. The left hand holds a vial with an arrow indicating movement toward the syringe held in the right hand, suggesting the process of drawing medication from the vial into the syringe.*
FDA Label Image

Figure M (Lanadelumab 31)

Figure M (Lanadelumab 31)
An instructional diagram showing a hand withdrawing liquid from a vial into a syringe. Inset detail highlights the vial stopper being punctured by the syringe needle, demonstrating proper technique for vial medication preparation.*
FDA Label Image

Figure N (Lanadelumab 30)

Figure N (Lanadelumab 30)
An instructional illustration depicting two hands preparing a syringe by drawing liquid from a vial. One hand holds the vial steady on a surface while the other pulls the syringe plunger to withdraw the medication. No text or branding is visible in the image.*
FDA Label Image

Figure O (Lanadelumab 32)

Figure O (Lanadelumab 32)
An instructional diagram showing the proper technique for drawing TAKHZYRO injection from a vial into a syringe. It depicts hands holding the vial upside down and a syringe, with an arrow indicating upward movement of the syringe plunger to withdraw the medication.*
FDA Label Image

Principal Display Panel (2 mL Syringe Carton)

Principal Display Panel (2 mL Syringe Carton)
TAKHZYRO (lanadelumab-flyo) injection 300 mg/2 mL (150 mg/mL) prefilled syringe packaging label from Takeda Pharmaceuticals America, Inc. The carton includes an image of the prefilled syringe and prescribing information references, along with storage instructions and a usage warning advising to read instructions before use. The package is labeled for subcutaneous use only and contains one single-dose 2 mL syringe.*
FDA Label Image

Principal Display Panel (150 mg/mL Syringe Label)

Principal Display Panel (150 mg/mL Syringe Label)
Label of TAKHZYRO 150 mg/mL (lanadelumab-flyo) injection. It specifies subcutaneous use only and that it comes in a single-dose prefilled syringe. The label also includes storage instructions and identifies Takeda Pharmaceuticals U.S.A., Inc. as the labeler.*
FDA Label Image

Principal Display Panel (150 mg/mL Syringe Carton)

Principal Display Panel (150 mg/mL Syringe Carton)
TAKHZYRO 150 mg/mL injection in a prefilled syringe packaging label for subcutaneous use. The label shows the product name, active ingredient lanadelumab-flyo, strength 150 mg/mL, and instructions including single-dose syringe and storage requirements. Produced by Takeda Pharmaceuticals America, Inc., it includes a barcode and visual instructions for removing the syringe from the tray.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.